Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching
Background: Cell and gene therapies are associated with uncertainty around their value claims at launch due to limitations of supporting clinical data; furthermore, their high costs present affordability issues for payers. Outcomes-based reimbursement can reduce payer decision uncertainty and improv...
Saved in:
Main Authors: | Jesper Jørgensen (Author), Laura Mungapen (Author), Panos Kefalas (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
by: Jesper Jørgensen, et al.
Published: (2020) -
Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test
by: Jesper Jørgensen, et al.
Published: (2017) -
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
by: Jesper Jørgensen, et al.
Published: (2019) -
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease
by: Jesper Jørgensen, et al.
Published: (2018) -
Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
by: Panos Kefalas, et al.
Published: (2018)